Search Results
Your search for ,ARE matches 21644 pages
Showing 7351 - 7400Repurposing Drugs for the Treatment of COVID-19
A vaccine for COVID-19 is currently the Holy Grail, but even if an effective vaccine were developed on a fast-track timetable, it may be effective in only a percentage of people, judging by existing flu vaccines, which show efficacy rates of approximately 45% and vary year by year. Until we have a...
Switch Control Inhibitor for GISTs Harboring Drug-Resistance Mutations: The INVICTUS Trial
In May 2020, the U.S. Food and Drug Administration (FDA) approved ripretinib for patients who have received prior treatment with three or more kinase inhibitors, including imatinib, for advanced gastrointestinal stromal tumors (GIST). The approval was largely based on the findings of the...
ASCO Provisional Clinical Update Offers New Recommendations for HBV Management in Patients With Cancer
Oncologists should consider screening all patients with cancer for the hepatitis B virus (HBV) prior to starting systemic anticancer therapy, with a focus on tests that use the hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), total Ig or IgG, and antihepatitis B surface...
Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGFR2 Fusions
At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues reported that third- and later-line treatment with the selective fibroblast growth factor...
Impact of Immune Checkpoint Inhibitors on COVID-19 in Patients With Cancer
In the time of COVID-19, there is much to learn about the intersection of coronavirus and cancer. One area of concern has been whether immunotherapies increase the risk of mortality in patients with cancer who also have COVID-19 infection. “To what extent immune checkpoint inhibition affects...
Essential Components of Palliative Medicine
Three years ago, ASCO updated its clinical practice guideline on the integration of palliative care into standard oncology care for patients with advanced cancer. The update was based on multiple randomized clinical trials showing better results with concurrent care than with usual oncology care...
Reevaluating the Delivery of Palliative Care in the Era of COVID-19
Palliative care services are so crucial to the well-being of patients with cancer that, in 2017, ASCO updated its clinical practice guideline on the integration of palliative care into standard oncology care.1 The updated guideline recommends that all patients with advanced cancer receive dedicated ...
Chemotherapy-Free Approaches in Follicular and Mantle Cell Lymphomas
As chemotherapy and chemoimmunotherapy regimens reach their maximal impact in follicular lymphoma and mantle cell lymphoma, clinicians are turning to chemotherapy-free approaches to achieve better control, less toxicity, and (hopefully) a cure. During the ASCO20 Virtual Education Program, Sonali M. ...
Past CMS and FDA Head Discusses Challenges in U.S. Health-Care Policy and Possible Solutions
As evidenced at this year’s ASCO20 Virtual Scientific Program, oncology science, technology, and clinical practice are evolving at a rapid pace, bringing new challenges to the efficient and ethical practice of cancer care at all levels. To shed light on some of the large-scale public health and...
Has Racial Disparity in Lung Cancer Incidence Lessened Among Young Adults?
A trend of higher lung cancer incidence rates in young Black people vs young White people in the United States has flipped, with the Black-White gap disappearing in men and reversing in women. The changing trends coincide with steeper declines in smoking among Black Americans, according to a new...
FDA Approves Daratumumab Plus Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
On August 20, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with carfilzomib (Kyprolis) and dexamethasone (DKd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy....
ASCO Updates Metastatic Pancreatic Cancer Guideline
ASCO has released an update to its Metastatic Pancreatic Cancer Guideline that includes recommendations for second-line treatment, including early biomarker testing for actionable genomic alterations.1 Last updated in 2018, this new version was triggered by novel evidence related to targeted...
FDA Pipeline: Priority Reviews for Immunotherapy Dose Regimen, Small Cell Lung Cancer; Fast Track Designations in Brain Cancer and Leukemia
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Reviews for a novel dosing regimen for durvalumab as well as for trilaciclib in small cell lung cancer; granted Fast Track designations to treatments for glioblastoma and B-cell acute lymphoblastic leukemia; and issued reports...
Link Between Gut Microbiome and Treatment Outcomes in Patients With Metastatic Kidney Cancer
Researchers have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes in those receiving immunotherapy. These findings were published by Salgia et al in European Urology. “We also reported the changes over time in the gut...
Updated Registry Data Confirm Higher COVID-19–Related Mortality in Patients With Cancer
“The distressing intersection of COVID-19 and cancer requires the use of large registries to acknowledge diversity,” stated Solange Peters, MD, PhD, President of the European Society for Medical Oncology (ESMO), in her keynote speech at the American Association for Cancer Research (AACR) Virtual...
Three Novel Genetic Variants Linked to Male Breast Cancer Discovered
Scientists have newly discovered three genetic changes that increase the risk of breast cancer in men. These findings were published by Maguire et al in the Journal of the National Cancer Institute. The researchers identified three common variations in DNA that predispose men to developing breast...
Current Lung Cancer Screening Guidelines May Underselect Black Ever-Smokers
Public health screening guidelines for lung cancer followed by the U.S. Preventive Services Task Force (USPSTF) and the Centers for Medicare & Medicaid Services (CMS) undercount eligible Black individuals, according to a study by Mary Pasquinelli, DNP, FNP-BC, and colleagues in press at the...
Molecular Testing in Metastatic Colorectal Cancer: Understanding How, When, and What to Profile
“In line with the emergence of targeted therapies, molecular biomarker testing in metastatic colorectal cancer has evolved over the past decade,” noted Jeanne Tie, MD, MBChB, FRACP, who acknowledged there is confusion about the best ways to use molecular testing in the clinic. Dr. Tie, who is...
Genomic Analysis of Cervical Cancer in Ugandan Patients
Nineteen of the 20 nations with the highest cervical cancer death rates are in sub-Saharan Africa. Now an international team has published the first comprehensive genomic study of cervical cancers in sub-Saharan Africa, with a focus on tumors from 212 Ugandan patients with cervical cancer. Their...
Dabrafenib Plus Trametinib for Patients With BRAF V600E–Mutated Cholangiocarcinoma
In a phase II trial reported by Vivek Subbiah, MD, and colleagues in The Lancet Oncology, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate in patients with BRAF V600E–mutated cholangiocarcinoma. This trial represents the first...
ASCO Members Can Access Special Offer for PPE Through Project N95: Register by August 24
Project N95, a not-for-profit organization, is offering access to ASCO’s qualifying U.S. members who are having difficulty obtaining personal protective equipment (PPE) for their patients and staff. Qualifying ASCO members will be able to make a one-time bulk purchase of the following PPE...
Balancing Efficacy and Safety of Targeted Therapy in Breast Cancer Care
Novel targeted therapies have increased the likelihood of cure and prolonged survival in many patients with advanced breast cancer (Table 1), but these new agents also carry toxicity profiles that vary greatly from those of traditional chemotherapy. During the ASCO20 Virtual Education Program,...
Aspirin May Accelerate the Progression of Advanced Cancers in Older Adults
Results from a recent clinical trial indicated that for older adults with advanced cancer, initiating aspirin treatment may increase their risk of disease progression and mortality. These findings were published by McNeil et al in the Journal of the National Cancer Institute. Study Background and...
Early Rituximab Intensification in R-CHOP for Diffuse Large B-Cell Lymphoma
As reported in the Journal of Clinical Oncology by Pieternella Johanna Lugtenburg, MD, PhD, and colleagues, the phase III Haemato-Oncology Foundation for Adults in the Netherlands (HOVEN)/ Nordic Lymphoma Group HOVON-84 trial showed that early rituximab intensification in R-CHOP-14 (rituximab plus...
Study Finds Radiotherapy May Be Associated With Long-Term Impact on the Cardiovascular and Metabolic Health of Childhood Cancer Survivors
A study by Wilson et al investigating the impact of radiation therapy on adult survivors of pediatric abdominal and pelvic tumors has found that these survivors were significantly more likely to have insulin resistance, high levels of triglycerides, and low levels of high-density lipoproteins...
Expert Point of View: Amit Mahipal, MBBS, MPH
Amit Mahipal, MBBS, MPH, Consultant, Associate Professor of Oncology, Mayo College of Medicine, Rochester, put the findings for tremelimumab/durvalumab into context regarding other studies evaluating checkpoint inhibitors in advanced hepatocellular carcinoma. In the current study by Kelly et al, he ...
Novel Tremelimumab/Durvalumab Regimen Active in Advanced Hepatocelluar Carcinoma
A single priming dose of tremelimumab and durvalumab, followed by monthly durvalumab, showed clinical activity in a predominantly second-line advanced hepatocellular carcinoma population, in a study reported at the ESMO World Congress on Gastrointestinal Cancer Virtual 2020.1 In a study of 332...
FDA Pipeline: Approval for First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic; Designations in Ovarian Cancer, Leukemia, and Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing technology to identify patients with non–small cell lung cancer (NSCLC) and specific types of EGFR mutations. The FDA also granted Fast Track...
Study Finds Residents of Low-Income Neighborhoods Have Less Access to ICU Beds Amidst Coronavirus Pandemic
A new study published by Kanter et al in Health Affairs sheds light on another reason why the coronavirus pandemic is disproportionately affecting individuals of lower socioeconomic status: residents in low-income neighborhoods lack access to intensive care unit (ICU) beds. While the shortage of...
Impact of Chromogranin A Expression on Disease Characteristics and Prognosis in Rectal Neuroendocrine Tumors
In a single-institution Korean study reported in the American Journal of Surgical Pathology, Kim et al found that chromogranin A expression in rectal neuroendocrine tumors is associated with more aggressive clinical characteristics and poorer prognosis. As stated by the investigators, “Although...
Providing Aid for Patients With Cancer Affected by the Beirut Explosion
The explosion of 2,750 metric tons of ammonium nitrate near the port of Beirut, Lebanon, on August 4 leveled whole sections of the city. The blast killed at least 200 people, injured more than 6,000, and left hundreds of thousands homeless. The blast also severely damaged Beirut’s already fragile...
Expert Point of View: Taimur Sher, MBBS, MD
Taimur Sher, MBBS, MD, Associate Professor of Medicine, Hematology and Medical Oncology Consultant, and Director of the Multi-Specialty Amyloidosis Group at the Mayo Clinic in Jacksonville, Florida, told The ASCO Post that shutting down the source of amyloidogenic light-chain production—the...
Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence
A study by researchers at the National Cancer Institute investigating mortality trends in lung cancer by subtype has found that population-level mortality from individuals with non–small cell lung cancer (NSCLC) fell sharply from 2013 to 2016, and that survival after diagnosis improved...
Subcutaneous Daratumumab Improves Outcomes for Patients With Light-Chain Amyloidosis, Study Finds
Patients with light-chain amyloidosis may soon have a new standard of care, according to data presented during the 25th European Hematology Association (EHA25) Virtual Annual Congress.1 Results of the phase III ANDROMEDA study have shown that adding subcutaneous daratumumab to the triplet...
New MASCC/ISOO Guidelines for Managing Mucositis
Updated clinical practice guidelines for managing mucositis—a common and often debilitating complication of cancer therapy—were recently published by Elad et al in the journal Cancer. The new guidelines summary, which will provide health-care professionals with better tools to deliver care for...
TITAN Trial: Apalutamide Adds to Options for Men With Metastatic Hormone-Sensitive Prostate Cancer
Androgen-deprivation therapy has been, and remains, the standard of care for patients with metastatic prostate cancer. Patients are often surprised to learn that was all we would do to control their disease and sometimes asked why they would not receive chemotherapy, as for other cancers. I would...
First-Line Atezolizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Cancer
As reported in The Lancet by Matthew D. Galsky, MD, of Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, and colleagues, the phase III IMvigor130 trial has shown prolonged progression-free survival with first-line atezolizumab plus platinum-based chemotherapy vs...
Expert Point of View: Toni K. Choueiri, MD
At the Genitourinary Highlights session of the ASCO20 Virtual Scientific Program, Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Boston, put the findings from KEYNOTE-426 into perspective. “This is an important update. The initial...
Novel Indications and New Drugs for the Treatment of Bladder Cancer
Pembrolizumab: On January 8, 2020, pembrolizumab (Keytruda) was approved by the U.S. Food and Drug Administration (FDA) for bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or...
Study Supports Pembrolizumab Plus Axitinib in Previously Untreated Advanced Renal Cell Carcinoma
Extended analysis of the phase III KEYNOTE-426 study upholds pembrolizumab plus axitinib as a preferred front-line regimen over sunitinib in patients with advanced sporadic renal cell carcinoma.1 These updated results were presented during the ASCO20 Virtual Scientific Program by Elizabeth R....
Expert Point of View: Philip J. Saylor, MD
Philip J. Saylor, MD, Attending Physician at Massachusetts General Hospital and Assistant Professor at Harvard Medical School, Boston, commented on this study. “The results presented are clearly exciting and cause us to look forward to a likely phase III study of this strategy. The high response...
Early Data Show Activity for Enfortumab Vedotin Plus Pembrolizumab in Advanced Bladder Cancer
It may be possible to use a platinum-free combination as first-line treatment for advanced or metastatic urothelial carcinoma in cisplatin-ineligible patients, if the results of the phase Ib/II EV-103 trial hold up. The combination of the newly approved antibody-drug conjugate (enfortumab vedotin)...
Many Choices Now for Men With Metastatic Hormone-Sensitive Prostate Cancer: How to Decide?
Based on the recently published ENZAMET, ARCHES, and TITAN trials,1-3 we now have several choices of systemic combination therapies for men with metastatic hormone-sensitive prostate cancer. Today, men are faced with decisions of androgen-deprivation therapy alone or combinations with abiraterone,...
Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma
In a study presented during the ASCO20 Virtual Scientific Program1 and published as a brief report in JAMA Oncology,2 Praful Ravi, MB, BChir, of the Dana-Farber Cancer Institute, Boston, and colleagues found that rechallenge with immune checkpoint inhibitor therapy was capable of producing...
Nonmetastatic Castration-Resistant Prostate Cancer
Nonmetastatic castration-resistant prostate cancer arises in the subset of men with biochemically recurrent disease (ie, rising prostate-specific antigen [PSA] level after definitive therapy in the absence of metastases) who develop PSA progression after chronic exposure to androgen-deprivation...
In Biochemically Recurrent Prostate Cancer, PSMA-Targeted PET/CT Imaging May Be Useful
Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, congratulated Dr. Hofman and coauthors on this first randomized trial of any PSMA-targeted therapy and was cautiously optimistic about the targeted radioligand treatment being adopted as post-docetaxel therapy in men with...
Lutetium-177–Labeled PSMA-617 Improves PSA Response in First Analysis From TheraP Trial in Metastatic Prostate Cancer
Initial results of the randomized phase II TheraP trial showed that therapy directed to prostate-specific membrane antigen (PSMA) with lutetium-177–labeled PSMA-617 (LuPSMA) significantly improved prostate-specific antigen (PSA) response compared with cabazitaxel in men with metastatic...
Genitourinary Oncology Highlights 2019–2020 Almanac
Over the past year, we have seen significant advances in the treatment of prostate, kidney, and urothelial cancers that will benefit patients now and in the future. We have learned about the final results of important clinical trials across multiple genitourinary cancers disease states leading to...
Robert A. Winn, MD, on the Impact of COVID-19 on Cancer Care Among Racial and Ethnic Minorities
Robert A. Winn, MD, of Virginia Commonwealth University and the Massey Cancer Center, discusses the COVID-19 pandemic and how it is exacerbating disparities in cancer care among racial and ethnic minorities and the medically underserved who are disproportionately affected by the coronavirus...
